Cargando…
A phase 1 study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy
Autores principales: | Stearns, V, Jacobs, L, Khouri, N, Jeter, S, Powers, P, Shahverdi, K, Brown, R, Rudek, M, Gabrielson, E, Zhang, Z, Tsangaris, T, Sukumar, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727122/ http://dx.doi.org/10.1186/1753-6561-3-S5-S28 |
Ejemplares similares
-
Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008) -
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009) -
Intraductal pegylated liposomal doxirubicin may achieve long term protection in HER2/NEU transgenic mice by restricting mammary gland outgrowth
por: Sukumar, S, et al.
Publicado: (2009) -
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
por: Valle, J W, et al.
Publicado: (2005) -
Pegylated liposomal doxorubicin (PLD) in daily practice—A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer
por: Wallrabenstein, T., et al.
Publicado: (2023)